1-3 of 3
Peter Szabo
Close
Sort by
Journal Articles

Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanova, Armin Ghobadi, Krish Patel, Jae H Park, Ian W. Flinn, Prutha Shah, Carol Wong, Cara Bickers, Peter Szabo, Lilly Wong, Bahram Valamehr, Siminder Atwal, Yu-Waye Chu, Rebecca Elstrom, Paolo Strati
Journal: Blood
Blood (2021) 138 (Supplement 1): 823.
https://doi.org/10.1182/blood-2021-151185
Published: 2021
Journal Articles

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells

Frank Cichocki, Jode P Goodridge, Ryan Bjordahl, Svetlana Gaidarova, Sajid Mahmood, Ramzey Abujarour, Zachary Davis, Hongbo Wang, Katie Tuininga, Behiye Kodal, Martin Felices, Paul Rogers, Greg Bonello, Janel Huffman, Thomas Dailey, Tom Lee, Peter Szabo, Lilly Wong, Sarah Cooley, Bahram Valamehr, Jeffrey S. Miller
Journal: Blood
Blood (2021) 138 (Supplement 1): 407.
https://doi.org/10.1182/blood-2021-148654
Published: 2021
Journal Articles

Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma

Krish Patel, Veronika Bachanova, Aaron M Goodman, John M. Pagel, Kelly Griffis, Marlisa Anderson, Siminder Atwal, Cara Bickers, Peter Szabo, Lilly Wong, Yu-Waye Chu, Rebecca Elstrom, Paolo Strati
Journal: Blood
Blood (2021) 138 (Supplement 1): 3873.
https://doi.org/10.1182/blood-2021-151520
Published: 2021